Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 13, 2025, by Catheter Precision, Inc., a Delaware corporation. The report details a material corporate action regarding the Company's capital structure, specifically the implementation of a reverse stock split previously authorized by stockholders at the Annual Meeting held on July 25, 2025.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The primary financial data relates to the Company's share count and capitalization:
- Pre-Split Outstanding Shares: Approximately 23,327,516 shares.
- Post-Split Outstanding Shares: Approximately 1,227,764 shares.
- Authorized Capital: Remains unchanged at 60 million shares of Common Stock and 10 million shares of Preferred Stock.
- Trading Symbol: VTAK (NYSE American).
- New CUSIP: 74933X 708.
Material Changes Versus Prior Period
The most significant change is the reduction in the number of issued and outstanding shares of Common Stock. The Company executed a 1-for-19 reverse stock split, effective at 12:01 a.m. Eastern Time on August 15, 2025. Consequently, every 19 pre-split shares were reclassified into one post-split share. No fractional shares were issued; instead, holders entitled to fractional shares received cash proceeds from the sale of aggregated fractional shares. Additionally, the number of undistributed shares covered by various active Registration Statements was proportionately reduced.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding operational performance. The Board of Directors exercised its discretion to select the 1-for-19 ratio within the range (1-for-5 to 1-for-19) approved by stockholders. The Company noted that the reverse split affects all stockholders uniformly and does not change percentage ownership interests or proportionate voting power, except for immaterial changes due to fractional share treatment. Adjustments were also made to the exercise prices and share counts of outstanding stock options, warrants, and preferred stock conversion ratios.
Investor Verification Checklist
- Verify the new CUSIP number (74933X 708) for trading and settlement purposes.
- Confirm the effective trading date of the split-adjusted shares (August 15, 2025).
- Review the treatment of fractional shares and any cash payments received in lieu thereof.
- Check the adjusted exercise prices and share quantities for any held stock options or warrants.
- Monitor the Company's compliance with NYSE American listing standards following the reduction in share count.